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Introduction 
Bronchogenic carcinoma has frequently been associated 
with para-neoplastic phenomena, ranging from mild 
systemic or cutaneous disease to hypercoagulability and 
severe neuromyopathic disorders (1). Non-specific inter- 
stitial pneumonia (NIP) was first described by Katzenstein 
and Fiorelli in 1994 (2). It has also been reported that NIP 
has been associated with collagen vascular disorders (2). We 
report a case of primary lung cancer associated with NIP 
and hypothesize that anti-human lung cancer cell anti- 
bodies play a role in the pathogenesis of NIP. 
Case report 
A 68-year-old man with a 2-month history of progressive 
dyspnoea on exertion attended the outpatient clinic. He had 
a dry cough and dyspnoea, but no sputum or fever. He was 
an office worker, who had not experienced any risk factors 
for occupational or environmental exposure to toxic 
materials, nor did he have hypersensitivity pneumonitis. 
His previous medical history was unremarkable except for 
smoking of 40 pack-years. There was no abnormal finding 
in chest X-ray which was taken one year ago. A rapidly 
symptomatic progression of his dyspnoea occurred 2 weeks 
after attending the outpatient clinic and he was subse- 
quently admitted to hospital. On physical examination, he 
was afebrile with a respiratory rate of 25 min-‘, blood 
pressure of 110 70 mmHg-‘, and a regular pulse rate of 
84 min-‘. The chest was symmetric and bibasilar and 
coarse crackles were ausculated. Laboratory data showed a 
normal blood count without eosinophilia. The electrolyte, 
renal and liver function tests were all normal. Arterial 
blood gas analysis showed PO2 of 78 mmHg, PCOz of 
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39 mmHg, AaDO of 32 mmHg and pH 7.45. Lung 
function studies showed a vital capacity of 61.4% and 
forced expiratory volume is 1s (FEVi) 81.3%. 
Chest X-ray and computerized tomography (CT) re- 
vealed a diffuse bilateral interstitial infiltrate as well as a 
nodule (sized 2.0 x 2.0 cm) in the right upper lobe (Fig. 1). 
Flexible bronchoscopy was non-diagnostic. The right 
side of the lung was opened at S3 (distant from the lung 
tumour) and needle biopsy of the tumour (right S*) 
performed. Pathological evaluation revealed squamous cell 
lung cancer in the right S2 as well as NIP (group II) in the 
right S3. Immunohistochemical staining of squamous cell 
lung cancer of the right upper lobe using monoclonal 
antibodies against several cytokeratins demonstrated cyto- 
keratin 8, 17, 18 and 19. 
Although the lung cancer was clinically staged at 1, the 
patient refused surgical treatment. Oral prednisolone (1 mg 
kg-’ day-‘) was initiated, and the bilateral infiltrating 
shadow disappeared. No exacerbation of interstitial pneu- 
monia was observed throughout more than 1 yr oral 
prednisolone treatment. 
To evaluate the existence of antibodies against lung 
proteins, Western immunoblot analysis was performed. 
SDS-polyacrylamide gel electrophoresis was performed 
according to Laemmli’s method (3) with a slight modifica- 
tion. Cell lysates of several lung cancer cell lines were then 
applied to a 10/20% SDS polyacrylamide gel, electrophor- 
esed (60 mA, 120 min). Proteins were then electrophor- 
etically transferred onto a nitrocellulose membrane using 
the method of Towbin ef af. (4) Proteins were detected by 
immunoblotting, using a patient’s serum (1:50 dilution), 
peroxidase conjugated goat anti-human IgG antibody 
(Sigma Immuno Chemicals, lot 094H-4810, St Louis, 
MO, U.S.A.), and stained with 4CN PLUS for chromo- 
genic detection of horseradish peroxidase (NEMTM Life 
Science Products, Boston, MA, U.S.A.). Western immuno- 
blot analysis showed that several antibodies against human 
lung cancer cell lines were found in this patient’s sera 
(Fig. 2). Among them, both anti-cytokeratin 8 antibody 
and anti-cytokeratin 19 antibody were characterized. 
However, one antibody against an unknown antigen was 
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FIG. 1. Chest computerized tomography (CT) findings on 
admission. Bilateral interstitial consolidation and a coin 
lesion (arrow) are demonstrated. 
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FIG. 2. Western immunoblot analysis using the patient’s 
sera against lysates of several lung cancer cell lines. Lane 
1; recombinant human cytokeratin 19, lane 2 ; 
Recombinant human cytokeratin 8, lane 3; A549 cell line 
(adenocarcinoma), lane 4; P.C9 (adenocarcinoma), lane 5; 
PC3 (adenocarcinoma), lane 6; RERF-LC-OK 
(adenocarcinoma), lane 7; LCljSQ (squamous cell lung 
cancer), lane 8; recombinant human cytokeratin 8, lane 9; 
recombinant human cytokeratin 19. The bands 
correspond cytokeratin 8 with increased amounts of 
carbohydrates (our preliminary data, arrow *), 
cytokeratin 8 (arrow **), unidentified antigen (arrow ** *) 
and cytokeratin 19 (arrow ****). Numbers on the left side 
represent molecular weight markers. 
also demonstrated (Fig. 2). Control sera from normal 
volunteers demonstrated no positive antibody against 
human lung cancer cell lines (data not shown). 
Discussion 
In this report, we described a case of lung cancer which is 
complicated with NIP. To our knowledge this is the first 
description of an association between NIP and lung cancer. 
In this patient’s serum, we also demonstrated antibodies to 
lung cancer cell lines, including anti-cytokeratin 8 as well as 
anti-cytokeratin 19. 
In 1994, Katzenstein and Fiorelli reported the histologi- 
cal features and clinical significance of NIP (2). The 
histological features of NIP include a varying degree of 
interstitial inflammation and fibrosis which appear to 
develop over a specific time (i.e., the process is temporarily 
uniform) (2). In addition, they also reported that 10 of their 
64 patients with NIP had an association with connective 
tissue diseases, including two patients with polymyositis (2). 
They also reported that the lesion of cellular interstitial 
pneumonia associated with dermatomyositis termed by 
Tazelaar et al. (5), corresponds well to that of NIP. This 
evidence suggests that the pathogenesis of NIP closely 
relates to autoimmune disorders. 
In the present study, we demonstrated anti-cytokeratin 8 
and 19 antibodies in the patient’s sera. Cytokeratin, which 
is one of the five different intermediate filaments, is 
characteristically expressed in epithelial cells (6). About 20 
different cytokeratin polypeptides have been identified in 
human epithelial cells (6). It has been reported that 
antibodies to cytoskeletal proteins are associated with some 
organ-specific autoimmune diseases (7). Cytokeratin-speci- 
fit antibodies appear to increase in diseases such as 
alcoholic liver disease and rheumatic disorders (8, 9), and 
several authors subscribe to the idea that anti-cytokeratin 
antibodies are formed in response to epithelial cell injury 
or death (10-13). However, none of these reports 
have described autoantibodies as specific to cytokeratin 8 
or 19. 
The significance of anti-cytokeratin 8 and 19 autoanti- 
bodies in this patient in the pathogenesis of NIP should also 
be discussed. The squamous cell lung cancer in this patient 
strongly expressed cytokeratin 8, 17, 18 and 19. There is a 
close temporal relationship between the diseases, together 
with neoplastigenic stimulation resulting in antibody 
formation or immune complex deposition in the lung and 
concomitantly in NIP. This is further supported by 
previous research which links lung cancer to other remote 
paraneoplastic syndromes (1). 
Iyonaga et al. revealed that hyperplastic type II cells 
strongly express cytokeratins 7, 8, and 19 (14). In addition, 
some studies have shown that antibodies can penetrate cells 
in viva (15). Therefore, antibodies which bind to cytokeratin 
8 and 19 may be pathologically significant, since defects in 
cytoskeletal organization are known to be capable of 
disrupting cell function of hyperplastic type II cells (16). In 
addition, cytokeratin 8 and 19 may be released from cancer 
cells as well as epithelial cells following cell injury. The 
resulting antibody-antigen interaction with immune com- 
plex formation could have a significant role in the 
perpetuation of the disease process, either by direct injury 
of epithelial cells or via local macrophage activation as they 
are cleared by phagocytosis (17). 
The possibility that other types of anti-cytokeratin 
antibodies exist in this patient cannot be excluded. 
However, we used several lung cancer cell lines and the 
patient’s serum only reacted to 54 kD (cytokeratin S), 45 
kD (unknown, possibly cytokeratin 18) and 40 kD 
(cytokeratin 19) proteins. Therefore, we believe that there 
are no significant antibodies against other cytokeratins. 
We could not rule out the possibility that the existence of 
cytokeratin 8 and 19 autoantibodies were a non-specific 
consequence of lung injury. Therefore, the significance of 
anti-cytokeratin 8 and 19 antibodies in the pathogenesis of 
NIP should be evaluated in future studies. In addition, 
although we could characterize two antigens as cytokeratin 
8 and 19, the other antigen should be identified in future 
studies. 
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In summary, we present a case of lung cancer associated 
with NIP. Anti-human lung cancer cell antibodies including 
anti-cytokeratin 8 and 19 antibodies may have played a role 
in the pathogenesis of NIP. 
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